Liver metastases of colon cancer: New therapeutic approaches. Neoadjuvant chemotherapy
Colon cancer witnesses one of most exciting and evolving times in the latest years. About 30% of patients with isolated liver colon metastases can now be cured through a multidisciplinary approach of the disease. New systemic treatments have moved the median survival of metastatic disease from 12 months four years ago to 20 months and beyond. Incorporation of new biologic treatments into the neoadjuvant setting may help to further improve historical outcomes and offers promise to continue this trend. Appropriate surrogate endpoints and optimal designs of clinical trials on neoadjuvant therapy as first or second-line of treatment are needed.
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Digital revista |
| Language: | English |
| Published: |
Alpe Editores, S.A.
2006
|
| Online Access: | http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0378-48352006000100002 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Colon cancer witnesses one of most exciting and evolving times in the latest years. About 30% of patients with isolated liver colon metastases can now be cured through a multidisciplinary approach of the disease. New systemic treatments have moved the median survival of metastatic disease from 12 months four years ago to 20 months and beyond. Incorporation of new biologic treatments into the neoadjuvant setting may help to further improve historical outcomes and offers promise to continue this trend. Appropriate surrogate endpoints and optimal designs of clinical trials on neoadjuvant therapy as first or second-line of treatment are needed. |
|---|